PURPOSE: To determine whether etoposide (VP16) is more effective when administered on a chronic schedule, women with clinically defined platinum-resistant epithelial ovarian cancer (EOC) were studied. PATIENTS AND METHODS: Thirty-one eligible women were treated with oral VP16. The first seven received a dose that varied depending on their body-surface area, but this proved too toxic, and so a fixed dose of 100 mg orally per day for 14 days every 3 weeks was used for the other subjects. RESULTS: The response rate was 26% (95% confidence interval [CI], 11% to 41%). The 28 women with cancer that had progressed while they were receiving a platinum analog had a response rate of 21% (95% CI, 6% to 36%). Response durations were short. CONCLUSION: When administered on this chronic schedule, VP16 has activity against platinum-resistant EOC.
No takes yet. Share an insight, caveat, or question.
Hoskins et al. (1994) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: